前列腺癌管理中长期地舒单抗相关颌骨坏死临床特征
该回顾性研究纳入624例接受地舒单抗治疗的前列腺癌骨转移患者,评估药物相关颌骨坏死(MRONJ)累积发生率及危险因素。MRONJ 1、2、3、6年累积发生率分别为4.6%、9.6%、20.3%、51.9%,严重MRONJ分别为2.4%、6.7%、13.1%、27.9%。独立危险因素包括疾病范围分级≥3、抗凝/抗血小板药物使用及6个月内牙科治疗史,给药间隔>1个月与风险降低相关。
要点
- 长期地舒单抗治疗前列腺癌骨转移患者MRONJ 6年累积发生率可达51.9%。
- 疾病范围分级≥3、抗凝/抗血小板药及近期牙科治疗是MRONJ独立危险因素。
- 地舒单抗给药间隔>1个月与MRONJ风险降低相关(HR 0.46)。
核心结论
- 长期地舒单抗治疗前列腺癌骨转移患者MRONJ累积发生率较高,需个体化治疗和早期预防。
主要发现
- MRONJ 1、2、3、6年累积发生率分别为4.6%、9.6%、20.3%、51.9%。
- 严重MRONJ(Stage≥2)1、2、3、6年累积发生率分别为2.4%、6.7%、13.1%、27.9%。
- 多因素分析显示疾病范围分级≥3(HR 2.00,P=0.009)、抗凝和/或抗血小板药物使用(HR 2.08,P=0.026)、6个月内牙科治疗史(HR 2.29,P=0.003)为MRONJ独立危险因素。
- 地舒单抗给药间隔>1个月与MRONJ风险降低相关(HR 0.46,P=0.041)。
关键数值与推荐
- MRONJ任何分期6年累积发生率为51.9%。
- 严重MRONJ(Stage≥2)6年累积发生率为27.9%。
- 疾病范围分级≥3的MRONJ风险HR为2.00(P=0.009)。
- 抗凝和/或抗血小板药物使用的MRONJ风险HR为2.08(P=0.026)。
- 6个月内牙科治疗史的MRONJ风险HR为2.29(P=0.003)。
临床怎么用
- 对长期地舒单抗治疗的前列腺癌骨转移患者应定期进行口腔评估和预防性牙科管理。
- 需关注抗凝/抗血小板药物使用及近期牙科治疗史等高危因素。
- 调整地舒单抗给药间隔可能有助于降低MRONJ风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the cumulative incidence of medication-related osteonecrosis of the jaw (MRONJ) in patients with prostate cancer and bone metastases receiving long-term denosumab treatment, and also the occurrence of severe MRONJ and risk factors associated with the development of both MRONJ and severe MRONJ. PATIENTS AND METHODS: This retrospective study included 624 patients with prostate cancer and bone metastases treated with denosumab between January 2015 and December 2024. Patients without bone metastasis or with insufficient clinical data were excluded. The study assessed the cumulative incidence of MRONJ, as well as risk factors associated with MRONJ of any stage and severe MRONJ (Stage ≥2). Cox regression analysis was used to identify independent risk factors. RESULTS: The cumulative incidence of MRONJ at 1, 2, 3, and 6 years was 4.6%, 9.6%, 20.3%, and 51.9%, respectively. For severe MRONJ, the corresponding rates were 2.4%, 6.7%, 13.1%, and 27.9%, respectively. Multivariate analysis identified the following independent risk factors for MRONJ: extent of disease grade ≥3 (hazard ratio [HR] 2.00, P = 0.009), use of anticoagulants and/or antiplatelets (HR 2.08, P = 0.026), and a history of dental treatment within the past 6 months (HR 2.29, P = 0.003). Denosumab administration at intervals >1 month was associated with a reduced risk (HR 0.46, P = 0.041). CONCLUSION: This study demonstrates that long-term denosumab treatment in patients with prostate cancer and bone metastases is associated with a substantial cumulative incidence of MRONJ. Key risk factors were identified, along with a modifiable factor that may reduce risk. These findings suggest that adjusting denosumab dosing schedules could help mitigate MRONJ risk, underscoring the need for personalised treatment plans and early preventive strategies.
引用
- Goto Y, Urabe F, Ogihara Y, et al. Clinical features of medication-related osteonecrosis of the jaw in prostate cancer management. BJU Int. 2025. PMID: 40682449. doi:10.1111/bju.16860
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。